NASDAQ:PACB Pacific Biosciences of California (PACB) Stock Forecast, Price & News $8.05 -0.30 (-3.59%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$7.96▼$8.3950-Day Range$8.05▼$13.5052-Week Range$5.46▼$14.55Volume5.83 million shsAverage Volume3.90 million shsMarket Capitalization$2.02 billionP/E RatioN/ADividend YieldN/APrice Target$13.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Pacific Biosciences of California MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside62.7% Upside$13.10 Price TargetShort InterestBearish13.50% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 14 Articles This WeekInsider TradingSelling Shares$1.25 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.18) to ($1.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.76 out of 5 starsMedical Sector836th out of 975 stocksAnalytical Instruments Industry25th out of 29 stocks 3.3 Analyst's Opinion Consensus RatingPacific Biosciences of California has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.10, Pacific Biosciences of California has a forecasted upside of 62.7% from its current price of $8.05.Amount of Analyst CoveragePacific Biosciences of California has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.50% of the outstanding shares of Pacific Biosciences of California have been sold short.Short Interest Ratio / Days to CoverPacific Biosciences of California has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Pacific Biosciences of California has recently increased by 2.30%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPacific Biosciences of California does not currently pay a dividend.Dividend GrowthPacific Biosciences of California does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PACB. Previous Next 2.9 News and Social Media Coverage News SentimentPacific Biosciences of California has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Pacific Biosciences of California this week, compared to 3 articles on an average week.Search Interest35 people have searched for PACB on MarketBeat in the last 30 days. This is an increase of 169% compared to the previous 30 days.MarketBeat Follows11 people have added Pacific Biosciences of California to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pacific Biosciences of California insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,247,090.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of Pacific Biosciences of California is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pacific Biosciences of California are expected to grow in the coming year, from ($1.18) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pacific Biosciences of California is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pacific Biosciences of California is -5.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPacific Biosciences of California has a P/B Ratio of 3.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Pacific Biosciences of California (NASDAQ:PACB) StockPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.Read More PACB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PACB Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comPacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Susan G. Kim Sells 19,257 SharesOctober 1, 2023 | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) PT Lowered to $9.00October 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 30, 2023 | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) Coverage Initiated at Sanford C. BernsteinSeptember 28, 2023 | msn.comBernstein Initiates Coverage of Pacific Biosciences of California (PACB) with Outperform RecommendationSeptember 27, 2023 | americanbankingnews.comPacific Biosciences of California (NASDAQ:PACB) Given "Neutral" Rating at Cantor FitzgeraldSeptember 26, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Pacific BiosciencesSeptember 18, 2023 | finance.yahoo.comIs Pacific Biosciences of California (PACB) Too Good to Be True? A Comprehensive Analysis of a ...October 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 14, 2023 | finance.yahoo.comUnraveling the Challenges Ahead for Pacific Biosciences of California Inc (PACB)September 14, 2023 | finance.yahoo.comUnveiling Pacific Biosciences of California (PACB)'s Value: Is It Really Priced Right? A ...September 14, 2023 | finance.yahoo.comStrength Seen in Pacific Biosciences (PACB): Can Its 8.9% Jump Turn into More Strength?September 13, 2023 | finance.yahoo.comPacific Biosciences of California Stock Clears Key Benchmark, Hitting 80-Plus RS RatingSeptember 12, 2023 | finance.yahoo.comPacBio Announces PacBio CapitalSeptember 10, 2023 | msn.comPacific Biosciences: Looks Appealing In The Fast-Growing Long-Read Sequencing MarketSeptember 8, 2023 | finance.yahoo.comCathie Wood's Buying These 3 Stocks Hand Over FistSeptember 7, 2023 | finance.yahoo.comPacBio Announces Collaboration with Leading Library Preparation Automation PartnersAugust 23, 2023 | msn.comCantor Fitzgerald Reiterates Pacific Biosciences of California (PACB) Neutral RecommendationAugust 8, 2023 | msn.comCathie Wood plows $6 million into Pacific BiosciencesAugust 7, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Buy Rating on Pacific Biosciences (PACB)August 7, 2023 | finance.yahoo.comTime to Nail Down Profits in One of My Top PicksAugust 4, 2023 | finance.yahoo.comPacBio Reports Equity Incentive Awards to New Employees Under Nasdaq Listing Rule 5635(c)(4)August 4, 2023 | finance.yahoo.comPacific Biosciences of California, Inc.'s (NASDAQ:PACB) P/S Is On The MarkAugust 3, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Pacific BiosciencesAugust 3, 2023 | finance.yahoo.comPacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue ViewAugust 3, 2023 | markets.businessinsider.comPacific Biosciences of California, Inc. Q2 Loss Decreases, beats estimatesAugust 3, 2023 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Pacific Biosciences (PACB)See More Headlines Receive PACB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pacific Biosciences of California and its competitors with MarketBeat's FREE daily newsletter. Email Address PACB Company Calendar Last Earnings8/02/2023Today10/03/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNASDAQ:PACB CUSIP69404D10 CIK1299130 Webwww.pacb.com Phone(650) 521-8000Fax302-636-5454Employees769Year Founded2004Price Target and Rating Average Stock Price Forecast$13.10 High Stock Price Forecast$17.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+62.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-314,250,000.00 Net Margins-218.43% Pretax Margin-218.43% Return on Equity-46.47% Return on Assets-16.00% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.20 Sales & Book Value Annual Sales$128.30 million Price / Sales15.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book3.23Miscellaneous Outstanding Shares250,560,000Free Float247,050,000Market Cap$2.02 billion OptionableOptionable Beta1.72 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Christian O. Henry M.B.A. (Age 55)Pres, CEO & Director Comp: $1.1MMs. Susan G. Kim (Age 47)Chief Financial Officer Comp: $564.87kMr. Mark Van Oene (Age 50)Chief Operating Officer Comp: $772.11kMr. Jeff Eidel (Age 46)Chief Commercial Officer Comp: $435.62kDr. Stephen Turner (Age 55)Co-Founder & CTO Ms. Michele Farmer CPA (Age 43)VP & Chief Accounting Officer Dr. Jonas Korlach Ph.D.Chief Scientific OfficerTrevin RardHead of Investor RelationsDr. Brett Atkins J.D.Ph.D., Gen. Counsel & Corp. Sec.Ms. Natalie WelchChief People OfficerMore ExecutivesKey CompetitorsOlink Holding AB (publ)NASDAQ:OLKCytek BiosciencesNASDAQ:CTKB10x GenomicsNASDAQ:TXGOmnicellNASDAQ:OMCLHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInsiders & InstitutionsSusan G KimSold 19,257 sharesTotal: $162,529.08 ($8.44/share)Barclays PLCBought 156,177 shares on 9/21/2023Ownership: 0.124%Christian O HenrySold 96,844 sharesTotal: $980,061.28 ($10.12/share)Christian O HenrySold 10,000 sharesTotal: $104,500.00 ($10.45/share)Wolverine Trading LLCBought 14,100 shares on 8/23/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PACB Stock - Frequently Asked Questions Should I buy or sell Pacific Biosciences of California stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PACB shares. View PACB analyst ratings or view top-rated stocks. What is Pacific Biosciences of California's stock price forecast for 2023? 9 brokerages have issued 12-month price targets for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $9.00 to $17.00. On average, they predict the company's stock price to reach $13.10 in the next twelve months. This suggests a possible upside of 62.7% from the stock's current price. View analysts price targets for PACB or view top-rated stocks among Wall Street analysts. How have PACB shares performed in 2023? Pacific Biosciences of California's stock was trading at $8.18 at the beginning of 2023. Since then, PACB stock has decreased by 1.6% and is now trading at $8.05. View the best growth stocks for 2023 here. When is Pacific Biosciences of California's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our PACB earnings forecast. How were Pacific Biosciences of California's earnings last quarter? Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings results on Wednesday, August, 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.06. The biotechnology company had revenue of $47.57 million for the quarter, compared to analyst estimates of $40.12 million. Pacific Biosciences of California had a negative trailing twelve-month return on equity of 46.47% and a negative net margin of 218.43%. Pacific Biosciences of California's revenue was up 34.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.34) earnings per share. What ETFs hold Pacific Biosciences of California's stock? ETFs with the largest weight of Pacific Biosciences of California (NASDAQ:PACB) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), AXS Green Alpha ETF (NXTE), ARK Innovation ETF (ARKK), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and BNY Mellon Innovators ETF (BKIV). What is Christian Henry's approval rating as Pacific Biosciences of California's CEO? 2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Pacific Biosciences of California own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA). What is Pacific Biosciences of California's stock symbol? Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB." How do I buy shares of Pacific Biosciences of California? Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Pacific Biosciences of California's stock price today? One share of PACB stock can currently be purchased for approximately $8.05. How much money does Pacific Biosciences of California make? Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.02 billion and generates $128.30 million in revenue each year. The biotechnology company earns $-314,250,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. How many employees does Pacific Biosciences of California have? The company employs 769 workers across the globe. Does Pacific Biosciences of California have any subsidiaries? The following companies are subsidiares of Pacific Biosciences of California: Circulomics, Omniome, PacBio Singapore PTE Limited, Pacific Biosciences (Shanghai) Co. Ltd., Pacific Biosciences Canada Limited, Pacific Biosciences Germany GmbH, Pacific Biosciences International LLC, Pacific Biosciences Japan GK, and Pacific Biosciences UK Limited.Read More How can I contact Pacific Biosciences of California? Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454. This page (NASDAQ:PACB) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.